1
|
Lin H, Buerki-Thurnherr T, Kaur J, Wick P, Pelin M, Tubaro A, Carniel FC, Tretiach M, Flahaut E, Iglesias D, Vázquez E, Cellot G, Ballerini L, Castagnola V, Benfenati F, Armirotti A, Sallustrau A, Taran F, Keck M, Bussy C, Vranic S, Kostarelos K, Connolly M, Navas JM, Mouchet F, Gauthier L, Baker J, Suarez-Merino B, Kanerva T, Prato M, Fadeel B, Bianco A. Environmental and Health Impacts of Graphene and Other Two-Dimensional Materials: A Graphene Flagship Perspective. ACS NANO 2024; 18:6038-6094. [PMID: 38350010 PMCID: PMC10906101 DOI: 10.1021/acsnano.3c09699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/06/2023] [Revised: 01/18/2024] [Accepted: 01/22/2024] [Indexed: 02/15/2024]
Abstract
Two-dimensional (2D) materials have attracted tremendous interest ever since the isolation of atomically thin sheets of graphene in 2004 due to the specific and versatile properties of these materials. However, the increasing production and use of 2D materials necessitate a thorough evaluation of the potential impact on human health and the environment. Furthermore, harmonized test protocols are needed with which to assess the safety of 2D materials. The Graphene Flagship project (2013-2023), funded by the European Commission, addressed the identification of the possible hazard of graphene-based materials as well as emerging 2D materials including transition metal dichalcogenides, hexagonal boron nitride, and others. Additionally, so-called green chemistry approaches were explored to achieve the goal of a safe and sustainable production and use of this fascinating family of nanomaterials. The present review provides a compact survey of the findings and the lessons learned in the Graphene Flagship.
Collapse
Affiliation(s)
- Hazel Lin
- CNRS,
UPR3572, Immunology, Immunopathology and Therapeutic Chemistry, ISIS, University of Strasbourg, 67000 Strasbourg, France
| | - Tina Buerki-Thurnherr
- Empa,
Swiss Federal Laboratories for Materials Science and Technology, Laboratory for Particles-Biology Interactions, 9014 St. Gallen, Switzerland
| | - Jasreen Kaur
- Nanosafety
& Nanomedicine Laboratory, Institute
of Environmental Medicine, Karolinska Institutet, 177 77 Stockholm, Sweden
| | - Peter Wick
- Empa,
Swiss Federal Laboratories for Materials Science and Technology, Laboratory for Particles-Biology Interactions, 9014 St. Gallen, Switzerland
| | - Marco Pelin
- Department
of Life Sciences, University of Trieste, 34127 Trieste, Italy
| | - Aurelia Tubaro
- Department
of Life Sciences, University of Trieste, 34127 Trieste, Italy
| | | | - Mauro Tretiach
- Department
of Life Sciences, University of Trieste, 34127 Trieste, Italy
| | - Emmanuel Flahaut
- CIRIMAT,
Université de Toulouse, CNRS, INPT,
UPS, 31062 Toulouse CEDEX 9, France
| | - Daniel Iglesias
- Facultad
de Ciencias y Tecnologías Químicas, Universidad de Castilla-La Mancha (UCLM), 13071 Ciudad Real, Spain
- Instituto
Regional de Investigación Científica Aplicada (IRICA), Universidad de Castilla-La Mancha (UCLM), 13071 Ciudad Real, Spain
| | - Ester Vázquez
- Facultad
de Ciencias y Tecnologías Químicas, Universidad de Castilla-La Mancha (UCLM), 13071 Ciudad Real, Spain
- Instituto
Regional de Investigación Científica Aplicada (IRICA), Universidad de Castilla-La Mancha (UCLM), 13071 Ciudad Real, Spain
| | - Giada Cellot
- International
School for Advanced Studies (SISSA), 34136 Trieste, Italy
| | - Laura Ballerini
- International
School for Advanced Studies (SISSA), 34136 Trieste, Italy
| | - Valentina Castagnola
- Center
for
Synaptic Neuroscience and Technology, Istituto
Italiano di Tecnologia, 16132 Genova, Italy
- IRCCS
Ospedale Policlinico San Martino, 16132 Genova, Italy
| | - Fabio Benfenati
- Center
for
Synaptic Neuroscience and Technology, Istituto
Italiano di Tecnologia, 16132 Genova, Italy
- IRCCS
Ospedale Policlinico San Martino, 16132 Genova, Italy
| | - Andrea Armirotti
- Analytical
Chemistry Facility, Istituto Italiano di
Tecnologia, 16163 Genoa, Italy
| | - Antoine Sallustrau
- Département
Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE, SIMoS, Gif-sur-Yvette 91191, France
| | - Frédéric Taran
- Département
Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE, SIMoS, Gif-sur-Yvette 91191, France
| | - Mathilde Keck
- Département
Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE, SIMoS, Gif-sur-Yvette 91191, France
| | - Cyrill Bussy
- Nanomedicine
Lab, Faculty of Biology, Medicine and Health, University of Manchester,
Manchester Academic Health Science Centre, National Graphene Institute, Manchester M13 9PT, United
Kingdom
| | - Sandra Vranic
- Nanomedicine
Lab, Faculty of Biology, Medicine and Health, University of Manchester,
Manchester Academic Health Science Centre, National Graphene Institute, Manchester M13 9PT, United
Kingdom
| | - Kostas Kostarelos
- Nanomedicine
Lab, Faculty of Biology, Medicine and Health, University of Manchester,
Manchester Academic Health Science Centre, National Graphene Institute, Manchester M13 9PT, United
Kingdom
| | - Mona Connolly
- Instituto Nacional de Investigación y Tecnología
Agraria
y Alimentaria (INIA), CSIC, Carretera de la Coruña Km 7,5, E-28040 Madrid, Spain
| | - José Maria Navas
- Instituto Nacional de Investigación y Tecnología
Agraria
y Alimentaria (INIA), CSIC, Carretera de la Coruña Km 7,5, E-28040 Madrid, Spain
| | - Florence Mouchet
- Laboratoire
Ecologie Fonctionnelle et Environnement, Université de Toulouse, CNRS, INPT, UPS, 31000 Toulouse, France
| | - Laury Gauthier
- Laboratoire
Ecologie Fonctionnelle et Environnement, Université de Toulouse, CNRS, INPT, UPS, 31000 Toulouse, France
| | - James Baker
- TEMAS Solutions GmbH, 5212 Hausen, Switzerland
| | | | - Tomi Kanerva
- Finnish Institute of Occupational Health, 00250 Helsinki, Finland
| | - Maurizio Prato
- Center
for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), 20014 Donostia-San
Sebastián, Spain
- Ikerbasque, Basque Foundation for Science, 48013 Bilbao, Spain
- Department
of Chemical and Pharmaceutical Sciences, University of Trieste, 34127 Trieste, Italy
| | - Bengt Fadeel
- Nanosafety
& Nanomedicine Laboratory, Institute
of Environmental Medicine, Karolinska Institutet, 177 77 Stockholm, Sweden
| | - Alberto Bianco
- CNRS,
UPR3572, Immunology, Immunopathology and Therapeutic Chemistry, ISIS, University of Strasbourg, 67000 Strasbourg, France
| |
Collapse
|
2
|
Nasrullah M, Meenakshi Sundaram DN, Claerhout J, Ha K, Demirkaya E, Uludag H. Nanoparticles and cytokine response. Front Bioeng Biotechnol 2023; 11:1243651. [PMID: 37701495 PMCID: PMC10493271 DOI: 10.3389/fbioe.2023.1243651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2023] [Accepted: 08/14/2023] [Indexed: 09/14/2023] Open
Abstract
Synthetic nanoparticles (NPs) are non-viral equivalents of viral gene delivery systems that are actively explored to deliver a spectrum of nucleic acids for diverse range of therapies. The success of the nanoparticulate delivery systems, in the form of efficacy and safety, depends on various factors related to the physicochemical features of the NPs, as well as their ability to remain "stealth" in the host environment. The initial cytokine response upon exposure to nucleic acid bearing NPs is a critical component of the host response and, unless desired, should be minimized to prevent the unintended consequences of NP administration. In this review article, we will summarize the most recent literature on cytokine responses to nanoparticulate delivery systems and identify the main factors affecting this response. The NP features responsible for eliciting the cytokine response are articulated along with other factors related to the mode of therapeutic administration. For diseases arising from altered cytokine pathophysiology, attempts to silence the individual components of cytokine response are summarized in the context of different diseases, and the roles of NP features on this respect are presented. We finish with the authors' perspective on the possibility of engineering NP systems with controlled cytokine responses. This review is intended to sensitize the reader with important issues related to cytokine elicitation of non-viral NPs and the means of controlling them to design improved interventions in the clinical setting.
Collapse
Affiliation(s)
- Mohammad Nasrullah
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada
| | | | - Jillian Claerhout
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada
| | - Khanh Ha
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada
| | - Erkan Demirkaya
- Department of Paediatrics, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada
| | - Hasan Uludag
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada
- Department of Chemical and Materials Engineering, Faculty of Engineering, University of Alberta, Edmonton, AB, Canada
- Department of Biomedical Engineering, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
| |
Collapse
|